All Stories

  1. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

    Article • EBioMedicine, May 2017, Elsevier

    Eric Mayoux

  2. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

    Article • Cardiovascular Diabetology, January 2017, Springer Science + Business Media

    Eric Mayoux

  3. Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114

    Article • Diabetes Care, November 2016, American Diabetes Association

    Eric Mayoux

  4. Response to Comment on Ferrannini et al. Diabetes Care 2016;39:1108–1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115–1122

    Article • Diabetes Care, October 2016, American Diabetes Association

    Eric Mayoux

  5. OS 05-04 EMPAGLIFLOZIN EXERTS CARDIO- AND NEPHRO-PROTECTIVE EFFECTS IN COHEN-ROSENTHAL DIABETIC HYPERTENSIVE RATS

    Article • Journal of Hypertension, September 2016, Wolters Kluwer Health

    Eric Mayoux

  6. Empagliflozin reverts the diet-induced NLRP-3 inflammasome activation.

    Article • Journal of Pharmacology and Experimental Therapeutics, July 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Eric Mayoux, Elisa Benetti

  7. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

    Article • Diabetes Care, June 2016, American Diabetes Association

    Eric Mayoux

  8. Characterization of Micro-RNA Changes during the Progression of Type 2 Diabetes in Zucker Diabetic Fatty Rats

    Article • International Journal of Molecular Sciences, May 2016, MDPI AG

    Eric Mayoux

  9. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

    Article • Diabetes, April 2016, American Diabetes Association

    Eric Mayoux

  10. CA-042: L'empagliflozine, un inhibiteur spécifique de SGLT2, prévient la sénescence induite dans les cellules endothéliales par des concentrations élevées de glucose

    Article • Diabetes & Metabolism, March 2016, Elsevier

    Eric Mayoux

  11. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin

    Article • Metabolism, February 2016, Elsevier

    Eric Mayoux

  12. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes

    Article • PLoS ONE, January 2016, PLOS

    Eric Mayoux, Professor Po Sing Leung

  13. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, June 2015, Springer Science + Business Media

    Eric Mayoux

  14. The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

    Article • PLoS ONE, November 2014, PLOS

    Professor Thomas Munzel or Muenzel, Eric Mayoux

  15. The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat

    Article • Journal of Pharmacology and Experimental Therapeutics, July 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Eric Mayoux

  16. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

    Article • Diabetes Metabolic Syndrome and Obesity, July 2014, Dove Medical Press

    Eric Mayoux

  17. Mammalian Sugar Transporters

    Article • June 2014, IntechOpen

    Eric Mayoux

  18. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension

    Article • AJP Renal Physiology, June 2014, American Physiological Society

    Eric Mayoux

  19. A promising combination for future treatment of type 2 diabetes: Coadministration of empagliflozin (SGLT-2 inhibitor) with linagliptin (DPP-4 inhibitor)

    Article • Diabetologie und Stoffwechsel, May 2014, Thieme Publishing Group

    Eric Mayoux

  20. Effects of empagliflozin on oxidative stress and endothelial dysfunction in STZ-induced Type 1 diabetic rat

    Article • Diabetologie und Stoffwechsel, May 2014, Thieme Publishing Group

    Eric Mayoux, Professor Thomas Munzel or Muenzel

  21. Fingerprints of hSGLT5 sugar and cation selectivity

    Article • AJP Cell Physiology, February 2014, American Physiological Society

    Eric Mayoux

  22. The Mammalian Solute Carrier Families SLC2 and SLC5: Facilitative and Active Transport of Hexoses and Polyols

    Article • January 2014, Springer Science + Business Media

    Eric Mayoux

  23. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice

    Article • AJP Renal Physiology, November 2013, American Physiological Society

    Eric Mayoux, Timo Rieg

  24. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia

    Article • AJP Renal Physiology, November 2013, American Physiological Society

    Eric Mayoux, Timo Rieg

  25. Effects of Sodium dependent Glucose Transporter 2 (SGLT2) Inhibition with Empagliflozin on Oxidative Stress and Endothelial Dysfunction in STZ-Induced Type I Diabetic Rat

    Article • Free Radical Biology and Medicine, November 2013, Elsevier

    Professor Thomas Munzel or Muenzel, Eric Mayoux

  26. Der Natrium-Glukose-Cotransporter-2 (SGLT-2)-Inhibitor Empagliflozin verbessert dosisabhängig die Insulinsensitivität bei db/db-Mäusen

    Article • Diabetologie und Stoffwechsel, April 2013, Thieme Publishing Group

    Eric Mayoux

  27. Der Natrium-Glukose-Cotransporter-2 (SGLT-2)-Inhibitor Empagliflozin hat eine dauerhafte Wirkung auf die Wiederherstellung der Glukose-Homöostase durch Erhalt der Beta-Zell-Masse in „Zucker Diabetic Fatty“ (ZDF)-Ratten

    Article • Diabetologie und Stoffwechsel, April 2013, Thieme Publishing Group

    Eric Mayoux

  28. Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine

    Article • Diabetes Obesity and Metabolism, June 2012, Wiley

    Eric Mayoux

  29. Alfuzosin Improves Penile Erection Triggered by Apomorphine in Spontaneous Hypertensive Rats

    Article • European Urology, January 2004, Elsevier

    Eric Mayoux

  30. Alfuzosin potentiates the proerectile effects of apomorphine in spontaneous hypertensive rats

    Article • European Urology Supplements, January 2002, Elsevier

    Eric Mayoux

  31. Effects of C-type natriuretic peptide on rat cardiac contractility

    Article • British Journal of Pharmacology, September 1999, Wiley

    Eric Mayoux

  32. Subcellular Creatine Kinase Alterations : Implications in Heart Failure

    Article • Circulation Research, July 1999, Wolters Kluwer Health

    Eric Mayoux

  33. Effet Paracrine de l’Endothélium de l’Endocarde sur le Myocarde: Rôle de l’Endothéline

    Article • Annales Françaises d Anesthésie et de Réanimation, January 1993, Elsevier

    Eric Mayoux

  34. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion

    Article • Circulation Research, January 1993, Wolters Kluwer Health

    Eric Mayoux

  35. Protective effect of dimethyl sulfoxide during ischemia

    Article • Journal of Molecular and Cellular Cardiology, June 1992, Elsevier

    Eric Mayoux

  36. Effect of pressure overload on cardiac Ca2+ antagonist binding sites of guinea pig. Comparison with the adaptational response of the hypertrophied rat heart

    Article • Cardiovascular Research, October 1991, European Society of Cardiology

    Eric Mayoux

  37. Effects of direct phosphorylation of contractile proteins by protein kinase a on force and cross bridge kinetics in skinned rat ventricular fibers N. Coutry, E. Mayoux, P. Lech�ne, R. Ventura-Clapier. U-241 INSERM, Universit� Paris-Sud, 91405 Orsay France

    Article • Journal of Molecular and Cellular Cardiology, June 1991, Elsevier

    Eric Mayoux

  38. The mechanism of positive inotropy induced by adenosine triphosphate in rat heart

    Article • Circulation Research, October 1990, Wolters Kluwer Health

    Eric Mayoux

  39. Cardiovascular effects of up 100-23, a novel cardiotonic drug

    Article • European Journal of Pharmacology, July 1990, Elsevier

    Eric Mayoux

  40. Calcium current in single cells isolated from normal and hypertrophied rat heart. Effects of beta-adrenergic stimulation

    Article • Circulation Research, July 1990, Wolters Kluwer Health

    Eric Mayoux

  41. ANF mRNA quantification in left ventricle of DOCA-salt rats treated with two hypotensive agents: Propranolol or rilmenidine. A tool for pharmacological studies

    Article • Journal of Molecular and Cellular Cardiology, June 1990, Elsevier

    Eric Mayoux

  42. Membrane proteins of the myocytes in cardiac overload.

    Article • British Journal of Clinical Pharmacology, February 1990, Wiley

    Eric Mayoux

  43. Calcium Current in Normal and Hypertrophied Isolated Rat Ventricular Myocytes

    Article • January 1990, Springer Science + Business Media

    Eric Mayoux

  44. Calcium channels in normal and hypertrophied rat heart

    Article • Journal of Molecular and Cellular Cardiology, May 1989, Elsevier

    Eric Mayoux

  45. Adaptational Process of the Cardiac Ca2+ Channels to Pressure Overload

    Article • Journal of Cardiovascular Pharmacology, October 1988, Wolters Kluwer Health

    Eric Mayoux

  46. Inotropic responsiveness to dihydropyridines and characterization of DHP receptors in normal and hypertrophied rat hearts D. Charlemagne, E. Mayoux, F. Callens, B. Swynghedauw

    Article • Journal of Molecular and Cellular Cardiology, June 1988, Elsevier

    Eric Mayoux

  47. Can changes in sarcolemmal membranes account for the altered inotropic responsiveness in hypertrophied heart?

    Article • Biochimie, April 1987, Elsevier

    Eric Mayoux

  48. Ca2+ channel antagonist receptors in normal and hypertrophied rat heart

    Article • Journal of Molecular and Cellular Cardiology, January 1986, Elsevier

    Eric Mayoux

  49. Digitalis receptors in normal and hypertrophied rat hearts. Differential effects of a Ca2+ free perfusion

    Article • January 1986, Springer Science + Business Media

    Eric Mayoux